GE Healthcare Technologies Inc. (NASDAQ: GEHC), today, is the focus of attention after unveiling AI tools for oncologists.
CareIntellect is a new solution from a medical technology company that aims to help doctors sort through the healthcare data which can be overwhelming. This leads to doctor burnout.
Deutsche Bank currently recommends GE Healthcare over GE Vernova Inc. (NYSE: GEV).
The analyst Nicole DeBlase remains bullish about GE Vernova – the manufacturer of energy equipment – despite the stock’s having more than doubled in value since 2024.
GE Vernova shares are headed to $354.
In a research note published today, Nicole DeBlase took over coverage for GE Vernova with a “buy rating” and set a target price of $354 that could indicate a 30% increase in the stock.
The New York listed firm will benefit from the continued investment in power generation assets due to the increasing demand for electricity because of “the electrification of everything, proliferation of AI data centres, decarbonization and the aging grid infrastructure”.
Analyst is confident that GEV’s profits and revenues will grow at the best rate in this environment. Deblase emphasized in her Monday research note a positive mix of growth in revenue and margins in GEV’s electrification division.
GE Healthcare is still a better choice for income-seeking investors, as GE Vernova currently does not pay a dividend compared to GEHC’s 0.13% combined yield.
What other factors could affect GEV’s share price?
GE Vernova’s wind turbine business is so large that Deutsche Bank believes it will benefit materially in the future. The wind is responsible for only 7.0% of world electricity, but this figure will rise to 25% by 2040.
The investment firm said that some of their optimism about GEV was also due to the gas-powered segment, which has been growing rapidly.
The demand for electricity is increasing, and so are gas turbine orders.
Nicole DeBlase, an analyst at GE Vernova, told her clients that the company would increase its HDGT production capacity to 77-80 unit/year in 2026.
She believes that this will eventually result in an increase of service orders/backlog.
Bullish calls on GE Vernova stocks arrive just days before the company is scheduled to release its third-quarter financial results. According to the consensus, the company’s revenue will increase by 10% in Q3 to $8.92 Billion and it is expected to earn $134.5 Million.
GEV stated in September that its revenues will be close to 35 billion dollars in 2024. Crispus Nyaga, our analyst, is bullish about GE Vernova’s shares over the long term.
The post GE HealthCare announces AI-based tools but GE Vernova shares offer greater growth potential could be updated as new information unfolds
This site is for entertainment only. Click here to read more
